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Abstract
The enzyme steroid sulfatase (STS) desulfates a variety 
of steroid compounds thereby altering their activity. 
STS is expressed in the skin, and its deficiency in this 
tissue has been linked to the dermatological condition 
X-linked ichthyosis. STS is also highly expressed in the 
developing and adult human brain, and in a variety of 
steroidogenic organs (including the placenta and go-
nads); therefore it has the potential to influence brain 
development and function directly and/or indirectly 
(through influencing the hormonal milieu). In this re-
view, we first discuss evidence from human and animal 
model studies suggesting that STS deficiency might 
predispose to neurobehavioural abnormalities and 
certain psychiatric disorders. We subsequently discuss 
potential mechanisms that may underlie these vulner-
abilities. The data described herein have potential im-
plications for understanding the complete spectrum of 
clinical phenotypes associated with X-linked ichthyosis, 
and may indicate novel pathogenic mechanisms under-
lying psychological dysfunction in developmental disor-
ders such as attention deficit hyperactivity disorder and 
Turner syndrome. 
© 2013 Baishideng. All rights reserved.
Key words: Acetylcholine; Aggression; Attention; Atten-
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Core tip: The enzyme steroid sulfatase (STS) cleaves sulfate 
groups from neuroactive steroid hormones thereby altering their 
activity. Here, we review cross-species evidence indicating that 
deficiency for this enzyme might influence behaviour and vulner-
ability to psychiatric illness; we then suggest potential mediating 
mechanisms. Understanding whether or not STS deficiency im-
pacts upon neural function, and if so, how, has potential implica-
tions for diagnosis, counselling and treatment in cases of X-linked 
ichthyosis (the dermatological condition associated with STS 
deficiency). Moreover, this understanding may provide more 
general novel insights into the pathogenesis of common and dis-
abling psychiatric disorders.
Trent S, Davies W. Cognitive, behavioural and psychiatric pheno-
types associated with steroid sulfatase deficiency. World J Transl 
Med 2013; 2(1): 1-12  Available from: URL: http://www.
wjgnet.com/2220-6132/full/v2/i1/1.htm  DOI: http://dx.doi.
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STEROID SULFATASE AND ITS ROLE IN 
BRAIN FUNCTION
Steroid sulfatase (STS, formerly known as arylsulfatase C) 
is an enzyme that acts as a homodimer within the endo-
plasmic reticulum to cleave sulfate groups from a variety 
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of  sulfated steroid hormones (notably 16α-hydroxy-
dehydroepiandrosterone, dehydroepiandrosterone, estrone 
and cholesterol sulfates), thereby altering their biological 
function; the desulfation of  several of  these compounds 
represents an initial step in the biosynthesis of  a number 
of  androgens and oestrogens[1]. The STS protein is ex-
pressed in a number of  tissues important in reproductive 
function including the placenta (highest expression), the 
ovaries, the testes and the mammary gland, as well as oth-
er non-reproductive tissues such as the liver and thyroid 
gland[2] (http://www.ncbi.nlm.nih.gov/unigene). 
Besides potentially influencing the development and/or 
ongoing function of  the aforementioned organs, STS rep-
resents an excellent a priori candidate modulator of  brain 
development and behaviour: during human embryogene-
sis, STS expression occurs throughout the thalamus, in the 
cortical plate, throughout the basal ganglia, in the hypo-
thalamus and anterior pituitary gland, and in the cerebellar 
neuroepithelium (a pattern largely consistent with that 
seen in other mammalian and non-mammalian species)[3], 
and with reported sulfatase activities in post mortem brain 
tissue of  adult humans[4]. Given this persistent brain ex-
pression, STS is likely to influence neural function directly; 
the substrates and products of  the enzyme are known to 
act as modulators at key sites of  neurotransmission in the 
brain, notably at γ aminobutyric acid type A, N-methyl-
D-aspartic acid and sigma (σ)receptors[1]. In addition, STS 
could exert a significant indirect influence on the brain 
via its role in androgen and oestrogen biosynthesis; these 
compounds can act systemically either to substantially and 
permanently alter brain development (“organisational ef-
fects’’) or to influence ongoing neural function via more 
subtle, potentially reversible “activational effects”[5].
In man, STS is encoded by the X-linked STS gene, 
which resides just outside pseudoautosomal region (PAR) 
1 at Xp22.3. STS escapes X-inactivation[6], and its Y ho-
mologue is pseudogenic as a consequence of  a pericentric 
inversion[7]. Together these attributes suggest the possibil-
ity that the gene might be expressed more highly in female 
than male tissues, and hence the activity of  the associated 
enzyme may be greater in the former sex; there is some 
empirical evidence that this may be the case[8-10]. A recent 
expression analysis has suggested that alternative first ex-
ons of  the STS gene may be employed in different tissues, 
with exons 0a and 1b being most abundant in the brain[11]. 
In rats, as in man, STS is X-linked, but the rat orthologue 
appears to be subject to X-inactivation[12]. In mice, STS 
is located within the PAR, and therefore by definition, 
escapes X-inactivation[13]. At the genetic level, there is 
considerable sequence divergence across species, although 
the function of  the encoded enzyme appears to be largely 
conserved[12,13].
STS DEFICIENCY AND EFFECTS ON 
GENERAL PHYSIOLOGY 
The vast majority of  cases of  STS deficiency (85%-90%) 
are caused by complete/partial deletions of  the STS gene, 
which typically also encompass genes immediately adja-
cent (HDHD1A, PNPLA4 andVCX); larger, rarer dele-
tions may encompass more distant genes including ARSE 
(encoding arylsulfatase E), NLGN4X (neuroligin 4X), 
other members of  the VCX family (encoding variably 
charged proteins) and KAL1 (encoding anosmin-1)[14-21]. 
About 5%-10% of  patients with STS deficiency present 
with a complex phenotype arising from the deletion of  
one or more of  the disease genes listed above: altered 
neuroligin 4X function has previously been suggested 
to account for sporadic cases of  autism and mental re-
tardation[20,22,23], deficiency for the VCX and VCX3A 
genes has been suggested as a possible cause of  mental 
retardation[24-26] (although there is some evidence that 
deletion of  these genes alone is not sufficient to cause 
this phenotype[27-29]), arylsulfatase E dysfunction has been 
linked to the skeletal disorder chondrodysplasia punc-
tata[30], and mutations within KAL1 (encoding anosmin-1) 
are associated with Kallman syndrome characterised by 
hypogonadotropic hypogonadism and anosmia[31]. The 
remaining 10% of  cases of  STS deficiency may be caused 
by a either variety of  point mutations within the STS 
gene resulting in aberrant gene expression/splicing or 
protein function[32-39], or, rarely, by a deleterious mutation 
in the autosomal gene encoding sulfatase modifying fac-
tor-1 (SUMF1) whose normal role is the posttranslational 
modification and catalytic activation of  a host of  sulfatase 
enzymes[40]. The majority of  genetic mutations at the STS 
locus are likely to be inherited rather than arising de novo[41]. 
The main phenotype associated with STS deficiency 
is a comparatively benign dermatological condition (X-
linked ichthyosis, XLI) in which affected individuals pres-
ent with large dark brown, adherent scales (particularly 
on the trunk, arms and legs) as a consequence of  the 
accumulation of  cholesterol sulfate in the membranes of  
stratum corneum cells[42]. Unsurprisingly, given that STS 
is X-linked, the vast majority of  subjects diagnosed with 
XLI are male, although skin dryness may be manifest in 
female heterozygotes. Other, less common, phenotypes 
associated with STS deficiency include corneal opaci-
ties which do not affect vision (10%-50% of  cases), and 
maldescent of  the testes during embryogenesis (20% of  
cases)[42]. Expectant mothers carrying fetuses affected 
by STS deficiency tend to exhibit delayed or prolonged 
labour as a consequence of  reduced placental oestrogen 
production and insufficient cervical dilation[43].
Confirmation of  STS deficiency in cases ascertained 
clinically (generally through their skin condition) may 
be done biochemically through showing absent enzyme 
activity, or genetically through identifying either a com-
plete/partial STS deletion or a deleterious point mutation 
within the gene[42]. Prevalence estimates for XLI based 
on clinical ascertainment have been in the range of  1 in 
3000-6000 males; however, prenatal screens identifying 
cases of  STS deficiency through low levels of  maternal 
serum oestrogen (unconjugated estriol) have reported 
higher prevalences of  approximately 1 in 1500 males[44,45]. 
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These data indicate a spectrum of  phenotypic conse-
quences of  enzyme deficiency, ranging from the most 
severe and easily ascertained (including contiguous gene 
syndromes), to milder forms (skin abnormalities only), to 
forms with no obvious clinical implications.
As the STS locus escapes X-inactivation, loss of  ge-
netic material from the short arm of  the X chromosome, 
or loss of  an entire X chromosome, in females as occurs 
in the developmental disorder Turner syndrome (TS)[46], 
will result in haploinsufficiency for STS. Whilst such 
haploinsufficiency is unlikely to result in phenotypes as 
obvious as those caused by complete enzyme deficiency, 
it may still feasibly contribute to the physiological and 
psychological abnormalities seen in TS[47]. Moreover, loss 
of  one STS allele in TS could expose deleterious muta-
tions on the remaining allele.
STS DEFICIENCY: EFFECTS ON 
BEHAVIOUR AND VULNERABILITY TO 
PSYCHIATRIC DISORDER
Possible role in disorders of attention
Emerging data from a variety of  experimental sources is 
providing converging evidence for a role for STS in the 
modulation of  attention. In the first systematic study of  
behaviour in individuals with XLI, Kent et al[20] showed 
that within a sample of  25 affected boys, ten met DSM-
IV criteria for diagnosis of  attention deficit hyperactiv-
ity disorder (ADHD), a neurodevelopmental condition 
characterised by inattention, pathological impulsivity and 
hyperactivity[48]; crucially, this sample was originally ascer-
tained on the basis of  low unconjugated estriol levels in 
their pregnant mothers and not on the basis of  the boys’ 
behaviour. Of  the ten individuals affected by ADHD, 
eight were diagnosed with primarily inattentive subtype 
of  the disorder, whilst the remaining two were diagnosed 
with the combined subtype (exhibiting evidence of  inat-
tention, and impulsivity and/or hyperactivity). Although 
this study did not employ a matched-control group, the 
40% overall ADHD diagnosis rate (and 32% inattentive 
ADHD diagnosis rate) within the XLI group was substan-
tially higher than that typically observed within the United 
Kingdom general population (4%-6% overall, 0.5% inat-
tentive). Importantly, whilst most boys diagnosed with 
inattentive ADHD had deletions spanning multiple genes, 
two individuals within this subgroup had presumed inac-
tivating point mutations within STS, indicating that STS 
dysfunction per se might predispose to inattention rather 
than the lack of  gene product from a contiguous gene. 
The findings of  the Kent et al[20] study are consistent with 
previous, more limited, case reports in the literature that 
have described individuals with contiguous Xp22.3 gene 
deletions and ADHD[49-51]. These initial data indicate 
that genetic screening of  large, behaviourally-ascertained 
ADHD samples and appropriate control samples to in-
vestigate the relative prevalence of  STS deletions/point 
mutations may be worthwhile.
Whilst work stimulated by the initial XLI findings has 
indicated no significant association between polymor-
phisms within STS and overall ADHD risk after correc-
tion for multiple testing[3,11], there does appear to be a 
significant, and replicable, association between variation 
at rs17268988 (located within intron 9 of  STS) and num-
ber of  inattentive symptoms within ADHD cohorts[3,52]; 
specifically, possession of  the minor G allele at this site 
(allele frequency about 0.25) is associated with a greater 
number of  inattentive symptoms, particularly in older 
children (> 9 years of  age). Whilst the genetic, cellular 
and neural mechanisms through which this association 
is mediated remain obscure, this finding provides fur-
ther evidence for a role of  STS in attentional function in 
neurodevelopmentally-compromised subjects; the extent 
to which an association between this genetic variant and 
attention exists in healthy individuals remains to be tested. 
Other polymorphisms across the STS gene (rs12861247, 
rs5978405 and rs5933863) have been shown to be sig-
nificantly associated with aspects of  cognitive function in 
males with ADHD as indexed by their performance on 
the comprehension, verbal IQ and picture completion 
Wechsler subtests, respectively[3]; as a small sample size 
was employed in this study these findings could be spuri-
ous, but if  confirmed, these associations could feasibly 
also be mediated via effects on attention.
One of  the most consistently reported neuropsycho-
logical findings in women with TS is inattention[53] which 
can be manifest as heightened distractability in real-life 
situations[54]. Rates of  ADHD have been reported to be 
up to eighteen-fold higher in the TS population than in a 
control female population[55]. By correlating individual TS 
subjects’ aggregate cognitive scores (partly based upon 
measures of  attention) with their karyotype, Zinn et al[56] 
concluded that haploinsufficiency for an 8.3Mb region 
of  chromosome Xp22.3 housing just 31 annotated genes 
(including STS) was critical in the development of  the 
characteristic TS cognitive profile. Given the results aris-
ing from the XLI and ADHD studies described above, 
STS is a candidate for the attentional component of  this 
profile. As such, it will be interesting to test whether 
those subjects with TS at greatest risk of  attention defi-
cits are hemizygous for the previously-identified risk 
alleles or deleterious mutations within STS. Should this 
prove to be the case, it would offer an opportunity to 
provide better genetic counselling and earlier clinical in-
tervention in cases of  TS.
Attention deficits are a prominent clinical feature of  
neuropsychiatric disorders other than ADHD, including 
autism[57-59] and schizophrenia[60]; cytogenetic deletions 
encompassing STS have been reported in individuals af-
fected by both disorders[20,61-65]. Psychiatric disorders as-
sociated with attention problems are more common (e.g., 
ADHD and autism[66]) or more severe (e.g., schizophre-
nia[67,68]) in males than in females. Thus, it is plausible that 
the lower expression/activity of  STS in males reduces 
their threshold of  vulnerability to attentional dysfunction. 
Recent data from animal model work appears to 
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substantiate the link between STS dysfunction and inat-
tention. Performance deficits in the 39, XO mouse (a 
model of  TS[69]) on the 5-choice serial reaction time task 
(5-CSRTT) assaying visuospatial attention could be res-
cued by the addition of  a small chromosome containing 
a small number of  additional genes including STS[70]. 
Subsequent work in another genetic model, the 39, XY*O 
mouse (in which the STS gene is deleted as a conse-
quence of  an end-to-end fusion of  the X and Y chro-
mosomes within the PAR), revealed that these mice are 
less able to detect stimuli of  short duration than wildtype 
mice[71]. Parallel studies in mice in which the STS axis was 
acutely pharmacologically modulated also showed effects 
on attention; specifically, administration of  the enzyme 
substrate dehydroepiandrosterone sulfate (DHEAS) en-
hanced a main index of  attention, whilst administration 
of  the specific enzyme inhibitor COUMATE impaired 
response accuracy under attentionally-demanding con-
ditions[71]. These pharmacological data, besides hinting 
that brain DHEA(S) levels may be a pertinent factor in 
attentional function, also indicate that ongoing STS activ-
ity could influence this psychological process. Given that 
peripherally-administered DHEAS is rapidly converted to 
DHEA within the mammalian brain[72], it is plausible that 
high levels of  the latter compound within the brain are 
associated with enhanced attention, but that low levels (as 
presumably occur in XLI patients and 39, XY*O mice) are 
associated with impaired attention. Whilst animal model 
work has provided some preliminary clues as to brain 
pathways that might be affected by STS and hence which 
might underpin its effect on attention (see later), more in-
depth analyses are clearly required. As STS appears to in-
fluence ongoing attentional processes, such analyses may 
feasibly identify novel therapeutic targets that could be 
acutely pharmacologically modulated in adolescents and 
adults affected by disorders of  attention. 
Aggression
Early genetic evidence in mice examining inter-male ag-
gression indicated that the Y chromosome PAR played 
an important role[73]; in mice, the PAR was originally 
thought to house just one gene (STS), but recently a sec-
ond mouse PAR gene Asmt (encoding the enzyme acetyl-
serotonin O-methyltransferase involved in the biosynthe-
sis of  melatonin from serotonin) has been identified[74]. 
However, in support of  STS as a candidate mediator of  
this phenotype, a strong relationship between protein lev-
els and aggression has been noted across several inbred 
mouse strains[75] and co-administration of  both DHEAS 
and COUMATE resulted in heightened aggression in 
the inbred CBA/H strain[76]; this latter result suggests 
that, in addition to modulating ongoing attentional func-
tion in mice, STS may also modulate ongoing levels of  
aggressive behaviour. Consistent with the results of  this 
pharmacological study, 39, XY*O male mice, which have 
low levels of  DHEA (and presumably elevated levels 
of  DHEAS), are hyper-aggressive towards their cage-
mates[77].
To date, there is little evidence from human studies 
that suggests an equivalent role for STS in modulating 
aggression: to our knowledge, abnormally high levels of  
overt aggression have not been reported in cases of  STS 
deletion, and within our Cardiff  ADHD sample we did 
not detect association between a number of  polymor-
phisms within STS and DSM-IV aggressive symptoms 
(albeit the case that the sample displayed low overall lev-
els of  aggression)[3]. There are two possible reasons for 
this apparent cross-species discrepancy: first, mouse brain 
function may be differentially affected by changes in STS 
levels, or the social structures imposed within groups of  
laboratory-housed mice might be conducive to elicting 
aggression. Alternatively, the phenotype of  elevated ag-
gression may be present in STS-deficient humans but it 
may be more subtle than in mice, or only observable upon 
provocation.
Whilst there is fairly convincing cross-species evi-
dence indicating a role for STS in attentional processes, 
and some data consistent with a role for the enzyme in 
aggression (in rodents at least), data suggesting a modula-
tory role in other behavioural phenotypes is more limited; 
this preliminary evidence is summarised below.
Impulsivity
In addition to being inattentive relative to 40, XY control 
mice, STS-deficient 39, XY*O mice appear to be less im-
pulsive, as indexed by their tendency to make fewer pre-
mature responses to a stimulus in the 5-CSRTT[71], and to 
better withhold responding on a murine analogue of  the 
human Stop Signal Reaction Time Task (SSRT); pharma-
cological manipulation of  the STS axis (i.e., COUMATE 
and DHEAS administration) also enhanced behavioural 
inhibition on the SSRT. These data hint that STS defi-
ciency in humans may also confer reduced impulsivity. 
Most research in psychiatry has focussed on pathological 
hyper-impulsiveness rather than the consequences of  
hypo-impulsivity, so exactly how this might be mani-
fest is unclear - perhaps such individuals would show a 
tendency towards apathy or extreme risk aversion? To 
date, there is no information available regarding whether 
XLI patients are particularly apathetic or cautious. At 
the neuropsychological level, we might predict that STS-
deficient subjects, like 39, XY*O mice, would demonstrate 
enhanced “stopping” on the SSRT. Testing for associa-
tion between polymorphisms across the STS gene and 
DSM-IV impulsive symptoms in a small sample of  boys 
with ADHD revealed no significant findings[3]. However, 
such a result is perhaps not surprising if  STS variation 
does generally result in reduced impulsivity, given that the 
ADHD population is, by definition, ascertained on the 
basis of  abnormally high levels of  impulsivity. 
Psychotic and mood disorders
Postpartum psychosis (PP) is a severe psychiatric condi-
tion occurring shortly after birth in 1-2 of  every 1000 
new mothers; it is characterised by hallucinations/de-
lusions, cognitive disorganisation, mood changes and 
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sleep abnormalities and can occasionally result in self- or 
infant-directed harm[78]. Whilst biology undoubtedly plays 
a role in PP susceptibility, as yet, well-defined risk factors 
are few and far between. The biggest risk factor appears 
to be a personal or family history for psychiatric (psy-
chotic) illness, with a strong and consistent relationship 
between prior bipolar disorder diagnosis and vulnerabil-
ity to PP; other risk factors include the extent to which 
circulating maternal oestrogen levels plummet following 
expulsion of  the placenta, and levels of  maternal stress[78]. 
It has been proposed that maternal STS deficiency might 
influence PP risk on the basis of  several observations 
(described in detail in a recent paper[79]): (1) levels of  the 
STS enzyme in the mammalian maternal brain specifi-
cally increase following parturition, hence perturbation 
of  the STS axis as a consequence of  enzyme deficiency 
may particularly impact upon behaviour at this timepoint; 
(2) the enzyme is highly expressed in the placenta where 
it is involved in the biosynthesis of  oestrogen precursors; 
decreased levels of  circulating oestrogens during preg-
nancy and in the postpartum period as a consequence of  
Sts deficiency may predispose to psychosis; (3) STS is a 
candidate gene underlying a quantitative trait locus for 
postpartum behavioural disturbance in pigs; (4) as dis-
cussed above, STS-deficiency in mice and humans predis-
poses to inattention (or “cognitive disorganisation”) and 
occasional aggression; and (5) STS is highly expressed in 
the thyroid gland, an organ whose dysfunction is often 
noted in cases of  PP. Given the overlap between bipolar 
disorder and PP, it is interesting to note that in a recent 
meta-analysis of  gene expression data from post mortem 
brain samples from patients with bipolar disorder, STS 
was one of  just a handful of  genes whose expression was 
consistently downregulated[80]; thus it plausible that STS 
deficiency predisposes primarily to bipolar disorder and 
thereafter to PP, or to PP directly, or to both disorders via 
shared neurobiological mechanisms. It is also noteworthy 
that the estimated prevalence of  female heterozygosity 
for a deleterious STS mutation (based on prenatal screen-
ing and XLI rates) is comparable to that of  PP (i.e., about 
1 in 750-3000 females), that the neurosteroid system has 
previously been implicated in psychotic disorders and in 
other postpartum conditions[81], that two female cases of  
paranoid schizophrenia possessed cytogenetic deletions 
spanning STS[61], and that deficiency for the STS para-
logue, ARSA (arylsulfatase A), has been linked to psy-
chotic phenotypes and postpartum depression[82-84].
A relationship between STS deficiency and a second 
mood disorder, unipolar depression, might also be con-
sidered, although currently the evidence for such a link 
is weak or anecdotal. One of  two females completely 
deficient for enzyme activity according to biochemical 
measurements (and therefore homozygous for an un-
defined STS mutation) was reported to have a history 
of  depression[85]. Moreover, we are aware of  one United 
Kingdom family in which X-linked ichthyosis appears to 
co-segregate with debilitating depression/anxiety.
Other behavioural endophenotypes
39, XY*O mice are hyperactive, particularly within a novel 
environment and during the night (i.e., during their active 
phase)[77], and there is a significant inverse relationship 
between evening activity in a novel environment and 
systemic levels of  the STS product DHEA[86]. 39, XY*O 
mice also exhibit increased response rates within oper-
ant behavioural tests where only one type of  response is 
required, which may reflect a greater tendency towards 
perseverative responding[86,87]. Finally, these mice tend to 
show heightened emotional reactivity relative to wildtype 
controls as indexed by their lack of  willingness to enter 
aversive (open, brightly-lit) spaces, and their increased 
levels of  urination and defecation in such spaces[77]. As 
39, XY*O mice also lack the PAR gene Asmt[86], theo-
retically, the hyperactivity, perseverative and emotional 
reactivity phenotypes in 39, XY*O mice could be due to 
the loss of  STS and/or Asmt (particularly given that the 
former and latter phenotypes are not elicited upon acute 
COUMATE administration[77]). However, the inverse as-
sociation between DHEA levels and hyperactivity tends 
to argue for a specific role for STS in this behaviour. To 
date, it has not proved possible to generate single-gene 
STS and Asmt knockout rodents; should such animals 
be created in the future, they could be used to dissociate 
between behavioural effects arising dues to STS and/or 
ASMT deficiency.
Hyperactivity and behavioural inflexibility (perse-
veration) have not consistently been reported as (endo) 
phenotypes associated with cases of  STS deficiency in 
humans. This could be because these phenotypes in mice 
are largely due to ASMT deficiency, because there is no 
association, because the phenotypes are relatively mi-
nor and do not impair everyday function, or because no 
systematic, objective, case-controlled behavioural stud-
ies have yet been performed for XLI (e.g., using activity 
monitors). The observation that 39, XY*O mice exhibit 
more anxiety-related behaviours than their wildtype coun-
terparts is consistent with anecdotal evidence suggesting 
anxiety in XLI patients, but clearly the veracity and mag-
nitude of  this association requires further exploration.
EFFECTS ON NEUROANATOMY AND 
NEUROCHEMISTRY: INSIGHTS FROM 
ANIMAL MODELS
The comparative rarity of  XLI patients, together with the 
relative inaccessibility of  the human brain, means that, 
to date, little is known about the neuroanatomical and 
neurochemical sequelae of  STS deficiency in man. Indi-
viduals in which STS is deleted have been reported to ex-
hibit cortical malformations including polymicrogyria[88] 
and heterotopia[89,90]; whilst these manifestations may be 
consistent with a role for STS in the developing cortex[3], 
given that these individuals lack multiple genes at Xp22.3, 
these abnormalities might equally likely be a consequence 
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of  the absence of  function of  one or more contiguous 
brain-expressed genes (e.g., HDHD1A). To uniquely as-
cribe these cortical phenotypes to STS deficiency, it will 
be necessary to examine the brains of  individuals with 
nonsense point mutations within STS either by in vivo 
neuroimaging or through analysing post mortem tissue. 
Rodent models are far more amenable to neurobio-
logical investigation than humans, and ongoing studies in 
genetic and pharmacological models have provided inter-
esting initial clues as to the neurochemical mechanisms 
underlying STS deficiency effects on behaviour. Relatively 
crude analyses of  whole tissue monoamine levels in the 
39, XY*O mouse have identified brain region-specific 
changes in the serotonin (5-HT) system (notably elevated 
5-HT levels in the striatum and hippocampus)[86,87]; these 
mutant mice also have increased hippocampal expression 
of  the Htr2c gene (encoding the 5-HT2c receptor) and 
reduced striatal levels of  the noradrenaline metabolite 
4-hydroxy-3-methoxyphenylglycol[87]. Correlational analy-
ses have indicated a positive linear relationship between 
hippocampal 5-HT levels and response rate/behavioural 
perseveration across two independent behavioural para-
digms[86,87] and between striatal 5-HT levels and activity[87]; 
whilst these observations suggest that the 5-HT system 
abnormalities may affect these behavioural endopheno-
types, an explicit causal link between the variables has 
yet to be established. Interestingly, serotonergic system 
dysfunction (including disruption of  5-HT2c receptor 
expression/function) has been implicated in many of  the 
psychiatric phenotypes linked to STS deficiency includ-
ing inattention[91,92], aggression[93], impulsivity[94], PP[95], 
anxiety and depression[96,97]. More refined analyses of  the 
relationship between analogues of  these behavioural/
psychiatric outcomes and 5-HT perturbation in the 39, 
XY*O mouse will be useful, notably investigating whether 
neurochemical changes within specific sub-regions of  
the hippocampus and striatum underlie the behavioural 
abnormalities. Although the most parsimonious explana-
tion for the neurochemical findings is STS deficiency[86], 
it is formally possible that they could arise due as a con-
sequence of  Asmt gene deletion. Again, examining single 
gene knockouts and/or assaying whether 39, XY*O phe-
notypes are recapitulated by acute enzyme inhibition will 
aid in distinguishing between these scenarios. Should a 
discrete STS-dependent change in 5-HT function be con-
firmed in mice, its potential functional relevance to hu-
man phenotypes might be tested through using positron 
emission tomography with serotonergic ligands in XLI 
patients[98]. 
To date, the neuroanatomy of  the 39, XY*O mouse 
has not been examined; future analyses might initially 
look for gross abnormalities in hippocampal and stria-
tal morphology for example, before investigating more 
subtle changes in cell number or subtype in these regions. 
Given the suggestion above that XLI may be associated 
with cortical abnormalities, examining the development 
and structure of  the cortex in STS-deficient mice may 
also be warranted. 
Rat studies in which STS is inhibited have also be-
gun to shed some light on the neurochemical pathways 
influenced by enzyme dysfunction. Again, these have 
emphasised the hippocampus, a key site of  neurosteroid-
mediated neurogenesis[99], as an important locus of  ongo-
ing Sts action. Initial studies using estrone-3-O-sulfamate 
(EMATE) as an inhibitor indicated that inducing acute 
enzyme dysfunction, particularly in combination with 
substrate (DHEAS) administration, could benefit learn-
ing and/or memory formation[100]. However, EMATE is 
oestrogenic[101], and thus it is difficult to ascertain whether 
its effects on cognition are due to its inhibitory and/or its 
oestrogenic role. In later studies, systemic enzyme inhibi-
tion using the compound [p-O-sulfamoyl-N-tetradecanoyl 
tyramine (DU-14), a compound with lower oestrogenicity 
than EMATE] administered chronically was shown to 
increase brain levels of  DHEAS[102], enhance hippocam-
pal release of  the neurotransmitter acetylcholine[103], and 
result in improved learning, spatial memory and context-
dependent fear memory[104,105]. The acetylcholine system 
has a long association with attentional function, and one 
obvious route through which STS axis variation might 
influence attention is via this intermediary mechanism[106]. 
Thus, future work might examine the effects of  STS in-
hibition, or STS gene deletion, on acetylcholinergic func-
tion in the hippocampus and other brain regions impli-
cated in attention, and how these induced neurochemical 
changes might then relate to measures of  (in) attention. 
Within the hippocampus, various serotonergic receptors 
are involved in controlling acetylcholine release[107]; hence, 
it will also be interesting to see whether there is any rela-
tionship between serotonergic and acetylcholinergic ab-
normalities induced as a consequence of  STS deficiency 
in this structure. 
CONCLUSIONS AND FUTURE 
DIRECTIONS
In the preceding text we have marshalled evidence from 
a variety of  sources which indicates that STS deficiency 
may elicit a multitude of  brain and behavioural pheno-
types of  relevance to psychiatric vulnerability. Clearly 
there is a need for further systematic work to specify the 
precise neural, behavioural and psychiatric endopheno-
types arising from this molecular abnormality, and to 
investigate their prevalence; such work may provide more 
general insights into behavioural and cognitive processes 
that commonly go awry in psychiatric conditions (e.g., at-
tention). Ideally, this work would involve the examination 
of  individuals with discrete mis-/nonsense point muta-
tions within the STS gene, or deletions solely encompass-
ing STS, in whom any phenotype could not be ascribed 
to missing contiguous genes; however, given the low 
frequency of  such mutations within the population, iden-
tifying such individuals will be difficult, and establishing 
reliable prevalence figures for particular phenotypes will 
be challenging. In light of  the arguments outlined above, 
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we propose that it would be worthwhile for patients with 
confirmed/suspected XLI to be asked by clinicians about 
any behavioural problems that they might have experi-
enced, given that any link between dermatologic abnor-
malities and such difficulties may not be intuitive.
Should elevated rates of  psychiatric illness be identi-
fied in enzyme-deficient individuals, it will be important 
to characterise their mechanistic basis i.e., whether they 
are related to loss-of-function of  the enzyme in the brain 
per se, to the pleiotropic, non-brain effects of  protein 
dysfunction, or to both (Figure 1). STS deficiency could 
influence brain function and behaviour directly (e.g., 
through modulating the serotonergic or acetylcholinergic 
systems). Alternatively, lack of  enzyme expression in ste-
roidogenic organs such as the placenta, gonads and mam-
mary gland[108] could result in reduced levels of  circulating 
steroid hormones (notably androgens and oestrogens) 
and subsequent downstream organisational and/or acti-
vational effects on brain development and function. Ani-
mals models in which STS function is perturbed will be 
of  use in distinguishing between these two possibilities. 
Furthermore, it is conceivable that an increased risk of  
some psychiatric disorders (e.g., depression and anxiety) 
could result from individuals having to live with potential-
ly disfiguring somatic conditions associated with enzyme 
deficiency including ichthyosis[42], hypogenitalism[109], or 
male-pattern baldness[110]; in support of  this notion, one 
study has shown that patients with ichthyosis have a lower 
health-related quality of  life[111]. Finally, it is conceivable 
that STS deficiency in the offspring could both result 
in increased risk of  psychiatric illness in that individual 
simply as a consequence of  neonatal distress arising from 
prolonged maternal labour[112-114], and, by the same gen-
eral stress-inducing mechanism, could increase risk of  
postpartum mental illness in the mother[115]. To determine 
whether these latter mechanisms may be important, com-
parison of  rates of  behavioural/psychiatric abnormalities 
in STS-deficient cases with those in subjects with other 
similar skin conditions for example, or exposed to other 
causes of  prolonged labour, may be valuable.
5-HT/ACh
abnormalities
Oestrogen/
androgen
biosynthesis
A
B
C
D X-linked ichthyosis
and other
associated
phenotypes
Maternal
stress
Prolonged
labour
STS-dependent
behavioural/psychiatric
phenotypes
Neonatal
distress
Figure 1  Mechanisms through which steroid sulfatase deficiency could theoretically influence neurobehavioural and psychiatric phenotypes. A: Loss of 
activity in the brain could directly influence neurodevelopment or ongoing function (e.g., via effects on the serotonergic or acetylcholinergic systems); B: Loss of activ-
ity in steroidogenic tissues (e.g., placenta, ovaries, mamary gland) could affect neurodevelopment and brain function via effects on levels of circulating oestrogens and 
androgens; C: High levels of stress associated with prolonged labour (as a consequence of enzyme dysfunction in the fetal portion of the placenta) could both potenti-
ate the development of postpartum illness in the mother, and could adversely affect neurodevelopment in the offspring; D: Living with potentially stigmatising condi-
tions such as ichthyosis and male pattern baldness could feasibly increase the risk of developing disorders such as depression and anxiety. STS: Steroid sulfatase.
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An alternative strategy for determining the conse-
quences of  acutely impaired STS function may be to 
explicitly test for brain and behavioural alterations in sub-
jects administered enzyme inhibitors. 667-COUMATE 
(Irosustat) has been proposed as a treatment for hor-
mone-dependent cancers[116,117] and for endometriosis[118], 
conditions where biosynthesis of  oestrogens and andro-
gens must be restricted. Although no obvious psychologi-
cal side-effects of  667-COUMATE treatment were re-
ported in the first clinical trial of  the drug in breast cancer 
patients[119], the animal data discussed above suggest that 
subtle effects on cognition (attention, impulsivity) and 
behaviour (aggression) might be anticipated. In assessing 
whether this is the case, potential confounding variables 
such as baseline rates of  depression, age, or the potential 
behavioural effects of  co-administered therapeutic drugs, 
in patients would have to be considered. 
Finally, taking a conceptually different approach, it 
will be interesting to see whether subjects with cytogenet-
ic duplications encompassing STS exhibit any clear brain 
or behavioural phenotypes. However, in most, if  not all, 
of  these cases, any data will be confounded by duplica-
tion of  contiguous brain-expressed genes. To date, the 
small number of  cases with Xp22.3 duplications reported 
in the literature either do not appear to exhibit any severe 
neuropsychological phenotypes[120], or present with rela-
tively non-specific phenotypes such as learning disability 
and/or developmental delay[121] depending upon the size 
of  the duplication. 
Understanding if, and how, STS deficiency influences 
vulnerability to psychiatric illness will be important in 
terms of  counselling for XLI (and potentially TS), and 
additionally may highlight novel therapeutically-amenable 
targets for common aspects of  psychological dysfunction.
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